CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...

holding more than 60% of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards’ SAPIEN ...

These results are the latest from the Evolut Low Risk clinical trial. The trial randomly assigned patients with severe aortic stenosis and low surgical risk to either TAVR or SAVR to replace their ...

In addition, Medtronic shares gained 2.5% on Mar. 31 after the company's positive five-year trial results showed its TAVR device, Evolut, delivered valve performance comparable to surgery ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX. Receive the the latest news, ...

Patients who received a single antiplatelet drug therapy— usually aspirin — after transcatheter aortic valve replacement (TAVR) had about half the risk of dying in the subsequent 6 months ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...